Patent intelligence · US
US 9556113
Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
Patent details — US 9556113
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2017
- Expiration
- Jan 26, 2037
- Applicant
- SOUTH DAKOTA BOARD OF REGENTS
- Claims
- 5
- CPC classes
- A61K, A61K31/225, A61K33/243, A61K45/06
Quick answer
US 9556113 (Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SOUTH DAKOTA BOARD OF REGENTS
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/225, A61K33/243, A61K45/06, A61K47/02, A61K47/10
More from SOUTH DAKOTA BOARD OF REGENTS
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9556113?
US 9556113 (Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9556113?
SOUTH DAKOTA BOARD OF REGENTS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9556113 expire?
Our index shows an expiration date of Jan 26, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.